HRP20040127A2 - Peptidic compounds selectively binding top p-selection - Google Patents

Peptidic compounds selectively binding top p-selection Download PDF

Info

Publication number
HRP20040127A2
HRP20040127A2 HR20040127A HRP20040127A HRP20040127A2 HR P20040127 A2 HRP20040127 A2 HR P20040127A2 HR 20040127 A HR20040127 A HR 20040127A HR P20040127 A HRP20040127 A HR P20040127A HR P20040127 A2 HRP20040127 A2 HR P20040127A2
Authority
HR
Croatia
Prior art keywords
compound
selectin
amino acid
vector
peptide
Prior art date
Application number
HR20040127A
Other languages
English (en)
Croatian (hr)
Inventor
Thomas
Johan Kuiper
Theodorus
Erik Anna Leonardus Biessen
Original Assignee
Yamanouchi Europ Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Europ Bv filed Critical Yamanouchi Europ Bv
Publication of HRP20040127A2 publication Critical patent/HRP20040127A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HR20040127A 2001-09-03 2002-08-28 Peptidic compounds selectively binding top p-selection HRP20040127A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01203314A EP1288222A1 (en) 2001-09-03 2001-09-03 Peptidic compounds selectively binding to P-selectin
PCT/NL2002/000566 WO2003020753A1 (en) 2001-09-03 2002-08-28 Peptidic compounds selectively binding to p-selectin

Publications (1)

Publication Number Publication Date
HRP20040127A2 true HRP20040127A2 (en) 2004-06-30

Family

ID=8180873

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040127A HRP20040127A2 (en) 2001-09-03 2002-08-28 Peptidic compounds selectively binding top p-selection

Country Status (16)

Country Link
US (1) US7531516B2 (enExample)
EP (2) EP1288222A1 (enExample)
JP (1) JP4227520B2 (enExample)
CN (1) CN100413883C (enExample)
AT (1) ATE446311T1 (enExample)
BR (1) BR0212219A (enExample)
CA (1) CA2459230C (enExample)
DE (1) DE60234108D1 (enExample)
ES (1) ES2337663T3 (enExample)
HR (1) HRP20040127A2 (enExample)
HU (1) HUP0401728A2 (enExample)
MX (1) MXPA04002055A (enExample)
NO (1) NO20040905L (enExample)
PL (1) PL369030A1 (enExample)
WO (1) WO2003020753A1 (enExample)
ZA (1) ZA200400956B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527086B1 (en) * 2002-08-09 2008-01-09 Astellas Pharma Europe B.V. Compounds binding to p-selectin
ATE444301T1 (de) 2002-10-11 2009-10-15 Astellas Pharma Europ B V Verbindungen auf glukosebasis mit affinitüt für p-selektin
EP1481683A1 (en) * 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. P-selectin targeting ligand and compositions thereof
US9833518B2 (en) 2012-04-13 2017-12-05 Case Western Reserve University Heteromultivalent particle compositions
US9107963B2 (en) * 2012-04-13 2015-08-18 Case Western Reserve University Heteromultivalent nanoparticle compositions
US10279347B2 (en) * 2014-04-08 2019-05-07 Dna Medicine Institute, Inc. Fluidics module
US11879012B2 (en) 2018-03-02 2024-01-23 Peter GILLIES Method of modulating cell proliferation
CN111671905B (zh) * 2020-06-23 2022-05-27 中国医学科学院医学实验动物研究所 P-选择蛋白糖蛋白配体-1作为靶点在制备预防和/或治疗动脉瘤的药物中的应用
US12150998B2 (en) 2021-04-20 2024-11-26 Bicycletx Limited Bicyclic peptide ligands specific for P-selectin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
WO1994005269A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of selectin binding
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6114517A (en) * 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US20020152495A1 (en) * 1999-01-15 2002-10-17 Toshiro Ito Plants having seedless fruit

Also Published As

Publication number Publication date
ES2337663T3 (es) 2010-04-28
CN100413883C (zh) 2008-08-27
HUP0401728A2 (hu) 2004-11-29
MXPA04002055A (es) 2004-07-08
CA2459230A1 (en) 2003-03-13
DE60234108D1 (en) 2009-12-03
CN1549824A (zh) 2004-11-24
EP1423413B1 (en) 2009-10-21
EP1288222A1 (en) 2003-03-05
PL369030A1 (en) 2005-04-18
US7531516B2 (en) 2009-05-12
JP4227520B2 (ja) 2009-02-18
US20050004035A1 (en) 2005-01-06
NO20040905L (no) 2004-05-26
CA2459230C (en) 2011-11-08
BR0212219A (pt) 2004-09-21
ZA200400956B (en) 2005-04-18
JP2005501544A (ja) 2005-01-20
WO2003020753A1 (en) 2003-03-13
ATE446311T1 (de) 2009-11-15
EP1423413A1 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
US20090062186A1 (en) Compounds Binding To P-Selectin
JPH10506608A (ja) 白血球接着のインヒビター
JPH10502349A (ja) インテグリンα▲下４▼β▲下１▼のＶＣＡＭ−１またはフィブロネクチンへの結合を阻害する方法
TW570929B (en) Cyclic adhesion inhibitors
JP2022502392A (ja) 経口剤形の製造方法
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
JP4227520B2 (ja) Ｐ−セレクチンに対して選択的に結合するペプチド化合物
WO2008094905A2 (en) Encapsulated hdl mimetic peptides
JP4771291B2 (ja) Ｐ−セレクチン標的リガンドおよびその組成物
WO1994011015A1 (en) Lipophilic peptide-based carriers for targeted drug delivery using rational drug-binding design
AU2002324363A1 (en) Peptidic compounds selectively binding to p-selectin
JPH06157588A (ja) 新規な細胞接着活性ペプチド誘導体
JPH06116289A (ja) 細胞接着性ペプチド配列複合体とその用途
HK1242610A1 (en) Methods for reducing cd36 expression
HK1197994A (en) Methods for reducing cd36 expression
HK1197994B (en) Methods for reducing cd36 expression
HK1123992A1 (en) Methods for reducing cd36 expression
HK1123992B (en) Methods for reducing cd36 expression
HK1173367B (en) Methods for reducing cd36 expression
HK1191025A (en) Inhibitors of apoptosis and uses thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050629

Year of fee payment: 4

PNAN Change of the applicant name, address/residence

Owner name: ASTELLAS PHARMA EUROPE B.V., NL

OBST Application withdrawn